Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of garetosmab for adults with the ultra-rare genetic disorder fibrodysplasia ...
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approve ...
Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in ...
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has drawn renewed market attention following a rating downgrade that contrasts ...
By Kamal Choudhury Feb 17 (Reuters) - Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but its modest advantage and higher rates of certain ...
In the current market session, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock price is at $797.57, after a 0.70% drop. However, over the past month, the company's stock spiked by 9.46%, and in ...
New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...
Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results